Epidemic Kaposi's sarcoma

Area of Science:

• Oncology
• Infectious Diseases
• Dermatology

Background:

• Kaposi's sarcoma (KS) is the most frequent malignancy in individuals with human immunodeficiency virus type 1 (HIV-1) infection.
• KS can lead to substantial patient morbidity and typically follows a progressive clinical course.
• While local therapies may palliate early-stage indolent KS, advanced or rapidly progressing disease necessitates systemic treatment.

Purpose of the Study:

• To review the current treatment strategies for Kaposi's sarcoma (KS).
• To discuss the role of various therapeutic agents in managing KS based on disease stage and patient immune status.
• To highlight emerging therapeutic approaches for KS.

Main Methods:

• Review of existing literature on Kaposi's sarcoma treatment.
• Analysis of therapeutic options including local therapies, interferon-alfa, and chemotherapy.
• Discussion of the role of antiretroviral agents in conjunction with KS treatment.

Main Results:

• Early indolent KS may be managed with local therapies for palliation.
• Interferon-alfa, with or without antiretroviral agents, is effective for patients with preserved immune function.
• Chemotherapy is the preferred treatment for symptomatic visceral, pulmonary, or rapidly progressive cutaneous KS.
• A growing number of treatment agents are available for KS management.

Conclusions:

• Treatment selection for KS depends on disease stage, progression rate, and immune status.
• Systemic therapies, including interferon-alfa and chemotherapy, are crucial for advanced KS.
• Future treatments may involve pathogenesis-based therapies targeting the KS-associated herpesvirus (KSHV).